Efficient protocols for the production of recombinant proteins are indispensable for the 33 development of the biopharmaceutical sector. Approximately 400 recombinant protein- 34 based biopharmaceuticals have been approved in recent decades, with steady growth 35 projected in the coming years. During the expression of a heterologous gene, the protein 36 quality control network is overcome by the disruption in protein homeostasis, leading to 37 protein aggregation. This phenomenon has been described in all expression systems 38 3 analyzed to date, including prokaryotic and eukaryotic host cells. These protein aggregates 39 have long been considered inert protein clumps devoid of biological activity and their 40 study has largely been neglected. However, in recent years, the classic view of protein 41 aggregates has completely changed with the recognition that these aggregates are a 42 valuable source of functional recombinant proteins. In this study, bovine interferon-43 gamma (rBoIFN-) was engineered to enhance the formation of protein aggregates by the 44 addition of aggregation-prone peptides (APPs) in the generally recognized as safe (GRAS) 45 bacterial Lactococcus lactis expression system. The L6K2, HALRU and CYOB peptides were 46 selected to assess their intrinsic aggregation capability to nucleate protein aggregation. 47 48 the total protein yield. However, fine physicochemical characterization of the resulting 49 intracellular protein nanoparticles (NPs), the protein released from these protein NPs, and 50 the protein purified from the soluble cell fraction indicated that the compactability of 51 protein conformations is directly related to the biological activity of variants of IFN-, 52 which is used here as a model protein with therapeutic potential. 53 Importance 54 The demand for recombinant proteins in the pharmaceutical industry is steadily 55 increasing. Emerging novel protein formulations, including naturally occurring protein NPs, 56 might be an alternative to soluble variants for fine analysis at the biophysical level. Such 57 analyses are important to address safety about biological molecules. 58 4 This study analyzes the effect of aggregation-prone peptides (APPs) on the improvement 59 of the production of naturally occurring protein nanoparticles (NPs) of interferon gamma 60 (IFN-) in the generally recognized as safe (GRAS) Lactococcus lactis expression system. In 61 addition, the fine physico-chemical characterization of the resulting proteins, either 62 obtained from the soluble or insoluble cell fractions, indicates that the selected 63 engineered proteins embedded in the protein NPs show higher compactability than their 64 soluble protein counterparts. Conformational compactability is directly related to the 65 biological performance of the recombinant IFN-. 66 67 73 variety of available expression vectors. In addition, its physiology has been exhaustively 74 studied, thus allowing the optimization of production processes (4). However, prokaryotes 75 show certain limitations, mainly the absence or limited ability to incorporate 76 posttranslational modifications in recombinant proteins. In some instances, those 77 modifications can be incorporated through the use of specific strain mutants or 78 transformed strains with genes of interest. However, the introduction of eukaryotic 79 5 glycosylations modifications in heterologous recombinant proteins is not feasible. Finally, 80 pro-inflammatory contaminant lipopolysaccharide (LPS) components of the outer leaflet 81 of the outer membrane of E. coli need to be removed from the purified protein to ensure 82 the safety of the final product, increasing the final cost (5,6). Prokaryotic endotoxin-free 83 expression systems are being explored to overcome this limitation, including E. coli LPS 84 mutant strains and generally recognized as safe (GRAS) microorganisms, such as 85
These APPs enhanced the tendency of the resulting protein to aggregate at the expense of Introduction 68 The efficient production and purification of recombinant proteins in a wide range of 69 expression hosts has driven the launch of a large number of biopharmaceutical products 70 (1, 2) . One of the most-studied expression systems is Escherichia coli (E. coli), which is also 71 one of the most-used gene expression systems for biopharmaceutical products (2,3). The 72 E. coli expression system is simple, fast, robust, productive and scalable and has a wide 8 transcriptional level (26). IFN- secretion, by natural killer (NK) cells and antigen- 145 presenting cells (APCs), enhances the innate immune response against detected 146 pathogens, while T-lymphocytes are involved in the secretion of IFN- in the adaptive 147 immune response (27, 28) . IFN- secretion is mainly regulated by other cytokines produced 148 by APCs, including IL-12 and IL-18. The activity of IFN- depends on its interaction, as a 149 dimer, with the IFN- receptor (IFNGR). IFNGR is a tetrameric complex formed by two 150 ligand-binding proteins (IFNGR1) and two signal-transducing proteins (IFNGR2). The 151 limiting factor in the transduction signal is the amount of IFNGR2 in the cell, which 152 provides a secondary phenotype of response in those cells in which the amount of IFNGR2 153 is limiting, leading to partial activation of the IFN--derived cascades. In that case, the 154 proapoptotic signal of IFN- is not manifested, and affected cells are able to proliferate 155 even in the presence of IFN- (26). 156 IFN- is used to prevent infectious diseases in patients suffering from chronic 9 intramammary infusion in productive dairy cows for mastitis treatment has been 167 proposed as a putative strategy to reduce the spread of antibiotic resistance among 168 zoonotic bacteria (41). Furthermore, the wide use of antibiotics in the prevention of 169 animal diseases and growth promotion appears to be a source of resistant bacteria, and 170 WHO and the United Nations have deployed global action against this threat to health 171 security. Therefore, the rational use of antibiotics in addition to the development of 172 immunostimulatory alternatives in the treatment and prevention of animal diseases may 173 play a role in the control of antibiotic resistance. 174 Interestingly, recombinant products for animal health must not only be stable and safely 175 and effectively delivered on a large scale and under standard conditions but also present 176 obvious advantages over existing products to prove its commercial viability. In this 177 context, approved recombinant human IFN- can be obtained from the E. coli expression 178 system, but novel protein formulations need to be developed. In fact, in most reported 179 studies of the expression and purification of IFN-, the recombinant protein is recovered 180 from the purified IBs through extensive denaturation-refolding processes (42-44).
10 the recombinant cytokine. Furthermore, we assessed the link between the biological 188 activities contained in protein NPs of IFN- variants and their physico-chemical 189 characteristics. We determined that the activity of the IBs is related to the specific 190 biological activity of the recombinant protein they contain, whereas the proportion of 191 released protein is not the main factor. The data presented here illustrate the great 192 potential of endotoxin-free protein NPs as active biomaterials to formulate, at the 193 nanoscale level, proteins of biomedical interest. a propeptide in the last few residues, rendering a mature protein of 15.6 to 17 kDa. 199 Heterogeneity of the C-terminus has been described, giving rise to variants of human ending at residues 150, 160 or 161 (45). Human IFN- is usually produced in the E. coli 201 expression system and is purified from IBs by using denaturing/refolding methodologies 202 since the soluble version of the protein is proteolyzed (42-44). The same strategy has been 203 used for mouse . In other approaches, recombinant proteins of bovine and ovine 204 origin are obtained from the soluble cell fraction of E. coli and Corynebacterium 205 glutamicum (47,48). We selected the rBoIFN- as a protein model to explore in detail In the present work, the mature bovine IFN- protein (residues 24 to 166) was 209 produced in L. lactis with different APPs to evaluate the ability of the peptides to increase 210 protein aggregation and to analyze the biological activity retained in the naturally 211 occurring protein aggregates. To improve gene expression, the DNA sequence of the 212 recombinant gene was codon optimized for the L. lactis expression system. Three 213 peptides, CYOB, HALRU and L6K2, were selected based on their predicted aggregation 214 propensity ( Table 1 and Fig. 1a ). AGGRESCAN was used to identify aggregation-prone 215 segments in proteins deposited in the Disprot protein database version v6.02 (49). CYOB 216 was selected as the peptide displaying the highest hot spot area (HSA). HALRU showed a 217 high normalized hot spot area (NHSA) and average aggregation-propensity hot spot 218 (a 4 vAHS) while maintaining a significantly high HSA value relative to the other identified 219 peptides. Finally, L6K2 was previously identified as a surfactant-like peptide with the 220 ability to enhance the aggregation propensity of several proteins (50). In the analysis, this 221 peptide exhibited high NHSA and a 4 vAHS values despite having shorter sequence. A linker 222 with a predicted random coil conformation was positioned between the IFN- and APP as 223 previously described (50). 224 In L. lactis, most of the protein is detected in the soluble cell fraction in the absence of any 225 of the APP (Fig. 1b ). This observation is in agreement with previous results for the 226 expression of the natural DNA sequence of the bovine IFN- gene in E. coli in which His-227 tagged rBoIFN- was purified by affinity chromatography from the soluble cell fraction 228 (48) . The presence of the APPs in the recombinant protein caused a noticeable shift of the 229 final products toward the insoluble cell fraction, as expected ( Fig. 1b ). The APP resulting in the highest aggregation tendency was the L6K2 peptide. In addition, the presence of an 231 APP tag also had a negative effect on the total recombinant protein produced in the cell. 232 This negative effect was maximal at 3 h, when protein levels of 13.82 ± 2.01 g/ml, 11.38 233 ± 0.36 g/ml, and 10.36 ± 0.45 g/ml were observed for the IFN- variants fused with the 234 L6K2, HALRU and CYOB peptides, respectively, compared with 211.99 ± 51.46 g/ml for 235 wild type IFN-. Therefore, the best APP in terms of aggregation propensity and protein 236 yield in the insoluble cell fraction, corresponded to the IFN- L6K2 formulation.
237 Surprisingly, the performance of this surfactant-like peptide exceeded the predicted 238 aggregation-prone capabilities of CYOB and HALRU peptides ( Table 1) .
239
Nanoarchitectonic characterization of protein nanoparticles. The morphometry of 240 purified protein NPs of the rBoIFN- variants was examined by field emission scanning 241 electron microscopy (FESEM; Fig. 2a ). The images revealed the presence of multimeric 242 complexes comprising discrete NPs in addition to isolated protein NPs (inset Fig. 2a ). First, 243 the NPs were similar to bovine IFN- protein NPs obtained previously in this expression 244 system (7). Z potential (ZP) measurements showed that all of the NPs presented negatively 245 charged surfaces with negative values ranging from -38 to -28 mV ( Fig. 2b ), indicating the 246 stability of the NP suspension. The higher values of ZP obtained for the IFN- variants 247 provide information about particle stability, as NPs displaying higher ZP values (higher 248 than +30 mV or lower than -30 mV) exhibit increased stability due to greater electrostatic 249 repulsion between particles (51).
250
Biological activity of soluble IFN- and nanoparticles of IFN-. The activity of IFN- is 251 usually determined by an antiviral assay (52). This assay must be performed in facilities 252 with an appropriate biosafety level, and viral stocks have to be maintained over time. 253 Therefore, alternative assays have been developed to simplify the procedure. One 254 approach to evaluate IFN- activity mediated by IFN--receptor binding is the detection of 255 kynurenine. The antiproliferative activity of IFN- in this assay is related to the induction of 256 the expression of the indoleamine-2, 3-dioxygenase (IDO) gene, which is the first and rate-257 limiting enzyme in tryptophan catabolism. IDO catalyzes oxidative cleavage of tryptophan 258 to N-formylkynurenine. Following a hydrolysis step, the latter is transformed into 259 kynurenine by Ehrlich's reagent, giving a yellow-colored compound absorbing at 490 nm 260 (53). To validate the assay, the activity of three soluble rBoIFN- proteins was tested by 261 using the kynurenine detection method ( Fig. 3a ). rBoIFN-_Std corresponded to a 262 commercially available mixture of bovine IFN- Gln24-Thr166 and Gln24-Arg162, both with 263 an N-terminal Met (R&D Systems). This protein preparation exhibited the lowest 264 dissociation constant (K D ) among the proteins purified from the soluble cell fraction ( Fig.   265 3a). The difference in this parameter with in-house IFN- produced in E. coli (rBoIFN-_E. 266 coli) was related to the Gln24-Arg162 variant, which was not included in the protein 267 preparation. However, this difference may also be attributable to other variables, such as 268 the buffer composition of the protein stock or the folding abilities of the transcribed 269 mRNAs from the two genes encoding the same protein but with different codon usages in 270 their sequences (54). The protein obtained from the L. lactis expression system displayed 271 less activity, which may be to differences in the way L. lactis and E. coli cope with gene codon usage that favor the specific activity of the protein obtained from E. coli. Other 273 variables may apply, such as the induction temperature (30 °C for L. lactis and 37 °C for E. 4a-4d). The commercial bovine IFN- exhibited a peak with a maximum at 7.6 nm, was 315 quite similar to the peak at 6.13 nm for the in-house version of IFN- produced in L. lactis.
This configuration might correspond to the dimeric form of the cytokine. However, the 317 IFN- obtained in-house in E. coli showed a tendency towards a larger size. Therefore, the 318 specific activity of the different rBoIFN-formats is not directly linked to the dimeric 319 configuration, which is the functional conformation when binding to the cell receptor, and 320 some other variables might be involved. When analyzing the size of the purified NPs, a 321 peak above 1000 nm was detected, which is above the upper sensitivity limit of the 322 equipment ( Fig. 4b ). The NPs were clustered in higher-order complexes from monomeric 323 versions of 200 nm ( Fig. 2a ). All samples exhibited the same profile. After solubilization of 324 the protein embedded in the NPs, the size of the remaining material remained above 1000 325 nm since the scaffold of the NPs retained the overall structure after the protein was 326 released (Fig. 4c ). The released protein showed a narrow dispersion ranging from the (Table 2) . Interestingly, for the 361 protein originating from the particulate form, a blue shift was observed comparde with 362 the soluble versions, and the CSM increased as itwa resolubilized (lines 2 and 4 of Table 2 ), 363 at least in versions with a percentage of release above 5 %. Interestingly, the CSM value of 364 the resolubilized rBoIFN-_L. lactis protein sample did not reach that of the soluble 365 counterpart (lines 3 and 4 of Table 2 ). When the APPs were incorporated in the 366 engineered protein constructs, the resolubilized proteins showed a decrease in the CSM 367 values compared with the protein NPs samples (lines 5 and 7). This behavior suggests a 368 possible self-arrangement of the tag within the protein that could replace water molecules 369 and increase the hydrophobicity of the Trp environment. The CYOB construct (line 6 of 370 Table 2 ) required a specific analysis as this tag contributes five additional Trp residues to 371 the whole protein structure. In this case, the resolubilized protein spectrum exhibited a 372 modest red shift (higher CMS value) compared with the particulate form, indicating that 373 the resolubilization process exposed some of the Trp residues to a hydrophilic 374 environment. The CSM values of the CYOB and HALRU protein NPs remained unaltered 375 after resolubilization (Table 2 , lines 6 and 7). These data are in accordance with the higher 376 stability of the particulate forms, which exhibited low levels of protein release. 377 The NP form of IFN- also favored the specific activity (insets, Fig. 3 the Bos taurus natural nucleotide sequence and in the L. lactis expression system from the 424 gene expressed in E. coli resulted in a protein product of larger size (Fig. 4) , confirming the 426 effects of the expression system and codon usage on the quality of the final product. 427 Differences in the compactability of protein samples with the same amino acid sequence 428 were also observed ( Table 2) . 429 In this context, the addition of APPs to the rBoIFN-protein improved the aggregation 430 profile of the produced protein ( Fig. 1b) . However, the presence of this type of peptides 431 had a negative effect on the overall production of the protein and, in the case of HALRU 432 and CYOB, a huge impact on biological activity ( Fig. 3 ). Therefore, AGGRESCAN software is 433 able to predict the propensity to aggregate of the resulting APP-containing recombinant 434 IFN- and is a reliable tool for analyzing solubility performance in the design of 435 recombinant genes. The size of the APP is an important parameter, and as a general rule, 436 the longer the aggregation peptide, the higher the HSA. However, small peptides with a 437 discrete HSA but high normalized and average HSA have also been reported to enhance 438 the aggregation of the accompanying proteins, as in the case of L6K2 (50). Surprisingly, the 439 L6K2 peptide also leads to the production of highly active protein in the protein NPs. The plasmid. The expression vector was transformed into the ClearColi® BL21(DE3) strain. 493 Electroporation was performed using a Gene Pulser from Bio-Rad with settings at 2400 V, 494 750 Ω and 25 μF in a pre-cooled 2-cm electroporation cuvette. The electroporated cells 495 were then supplemented with 900 μl of lysogeny broth (LB) and incubated for 1 h at 37 °C. 496 The cells were then plated on LB-agar plates containing ampicillin (100 μg/ml) and 497 incubated at 37 °C overnight. For all clones, in the sequence design we added an NcoI 498 restriction site at the 5′ end followed by the nucleotides CA to restore the reading frame. 499 This cloning strategy adds an Ala to the N-terminus of the protein. Therefore, the 500 recombinant proteins were produces as the mature form of the IFN-γ (from Gln24 to 501 Thr166 NP_776511.1) with an additional Ala at the N-terminus to restore the frameshift 502 introduced by the NcoI restriction site (Fig. 1a ). 504 APPs were selected by scanning the Disprot v6.02 database (49) with AGGRESCAN 505 software (76). We selected two unstructured regions from two different proteins that 506 displayed a higher HSA. This selection was based on the assumption that APPs in solvent-507 exposed regions were the best candidates for the purposes of this study. Additionally, 508 L6K2 was selected based on previous experimental results (50) after analysis with 509 AGGRESCAN showed that this peptide had a high NHSA and high a 4 vAHS. grown for 5 h. Antibiotics were used for plasmid maintenance at the following 544 concentrations: chloramphenicol (5 μg/ml) and erythromycin (2.5 μg/ml) for L. lactis and 545 ampicillin (100 μg/ml) and streptomycin (30 μg/ml) for ClearColi. 546 Once produced, the protein NPs were purified using the purification protocol described 547 previously (7), including, at the beginning of the process, a mechanical disruption step by 548 French press. The protocol was performed under sterile conditions and all incubations and emission slits were set at 5 nm. The excitation wavelength ( ex ) was set at 295 nm. 627 Emission spectra were acquired within a range from 310 to 550 nm. The protein 628 concentration was 0.3 mg/ml in PBS. To evaluate conformational differences between the 629 proteins, we applied the CSM. CSM is the weighted average of the fluorescence spectrum 630 peak. 631 The CSM was calculated for each of the fluorescence emission spectra (79) according to 632 Eq.2, where I i is the fluorescence intensity measured at wavelength  i . 
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